Eric Topol flags WSJ profile of OpenEvidence, the ad-supported AI used by millions of doctors
EricTopol · x · 2026-11-16
Eric Topol shares a WSJ column profiling OpenEvidence, the AI platform trained on major peer-reviewed medical journals, while questioning its "saving lives" claim. Key points:
- Built with a "Copernican" architecture that lets the model say "I don't know" to reduce hallucinations; reviewed by editorial boards including NEJM.
- Handled 47 million queries in October; used daily by 15M healthcare professionals in the US.
- Free, ad-supported model: pharma companies can surface drug info to physicians and match patients to clinical trials (a third of the $50B/year US trials fail to recruit patients).
- CEO Daniel Nadler cites an internal analysis linking access to declining all-cause mortality in men under 30 — the claim Topol is skeptical of.
More from AGI Musings
- Most AI books are marketing products, not thinking: a founder's critique of AI hype authors — mitchdeg · 2026-11-16
- AI determinism critiques secretly assume humans have nonphysical souls — AndyMasley · 2026-11-16
- Mid-size firms and regulated industries will lag far behind on AI adoption — jdjohnson · 2026-11-16
- "The conference-paper game is 100% dead": researcher urges GitHub-first research output — DimitrisPapail · 2026-11-16
- DeepMind researcher on doing research in the AI era: minimize friction to excellent work — DimitrisPapail · 2026-11-16
- Turing Award winner David Patterson argues superintelligence should replace lawyers entirely — davidpattersonx · 2026-11-16